וילדאמד אס.קיי. 501000 מג
k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - vildagliptin 50 mg; metformin hydrochloride 1000 mg - metformin and vildagliptin
וילדאמד אס.קיי. 50850 מג
k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - vildagliptin 50 mg; metformin hydrochloride 850 mg - metformin and vildagliptin
יוקריאס 501000 מג
novartis israel ltd - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - metformin hydrochloride 1000 mg; vildagliptin 50 mg - metformin
יוקריאס 50500 מג
novartis israel ltd - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - metformin hydrochloride 500 mg; vildagliptin 50 mg - metformin
יוקריאס 50850 מג
novartis israel ltd - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - vildagliptin 50 mg; metformin hydrochloride 850 mg - metformin
מטילדה 501000 מג
teva israel ltd - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - metformin hydrochloride 1000 mg; vildagliptin 50 mg - metformin
מטילדה 50850 מג
teva israel ltd - metformin hydrochloride; vildagliptin - טבליות מצופות פילם - metformin hydrochloride 850 mg; vildagliptin 50 mg - metformin
יוקריאס 50/850 מ"ג
novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
יוקריאס 50/500 מ"ג
novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
גאלבוס 50 מג
novartis israel ltd - vildagliptin - טבליה - vildagliptin 50 mg - vildagliptin